Antineoplaston Therapy in Treating Patients With Refractory Stage IV Prostate Cancer
Status:
Withdrawn
Trial end date:
1997-02-20
Target enrollment:
Participant gender:
Summary
Current therapies for Refractory Stage IV Prostate Cancer provide very limited benefit to the
patient. The anti-cancer properties of Antineoplaston therapy suggest that it may prove
beneficial in the treatment of Refractory Stage IV Prostate Cancer.
PURPOSE: This study is being performed to determine the effects (good and bad) that
Antineoplaston therapy has on patients with Refractory Stage IV Prostate Cancer.